[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemolytic-disease-of-newborn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemolytic-disease-of-newborn":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":14,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100607418","risk-factors-and-clinical-outcomes-of-neonatal-anemia-in-nicu-100607418",false,"NCT07188298","Risk Factors and Clinical Outcomes of Neonatal Anemia in NICU","Risk Factors, and Clinical Outcomes of Neonatal Anemia in the NICU of a Tertiary Care Hospital","Inclusion Criteria:\n\n* All live-born neonates admitted to the NICU within the first 24 hours of life.\n* Both term and preterm infants.\n\nExclusion Criteria:\n\n* Major congenital malformations\n* Chromosomal abnormalities or genetic syndromes\n* Neonates with a previous blood transfusion before study enrollment",true,"ALL","1 Day","30 Days",{"count":21,"type":22},40,"ESTIMATED","OBSERVATIONAL",[25,26,27],"Hemolytic Disease of Newborn","Anemia of Neonates","Sepsis","NOT_YET_RECRUITING","2025-09-20",{"date":31,"type":32},"2025-09-23","ACTUAL",{"date":34,"type":22},"2025-10-25",{"date":36,"type":22},"2026-11-01",{"name":38,"class":39},"Assiut University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":17,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100379264","safe-threshold-to-discontinue-phototherapy-in-hemolytic-disease-of-newborn-100379264","NCT04218318","Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn","Safe Threshold to Discontinue Phototherapy in Term and Late Preterm Infant With Hemolytic Disease of Newborn: A Randomized Controlled Trial","Inclusion Criteria:\n\nHealthy term and late-preterm neonates more than or equal 35 weeks gestation with hemolytic disease of newborn will be included. Enrolled infants should have evidence of hemolysis as defined by any of the following criteria:\n\n1. positive DAT and blood group iso-immunization (ABO \u002F RH incompatibility);and \u002For\n2. HGB decline by 2g\u002Fdl within 24hour.\n\nExclusion Criteria:\n\n* Major congenital abnormalities,\n* Surgical problems,\n* Direct hyperbilirubinemia\n* Sepsis","1 Hour","14 Days",{"count":50,"type":22},84,"INTERVENTIONAL",[53],"NA","We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn.\n\nObjectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.",[25,56],"Neonatal Hyperbilirubinemia",[58,59,60,61,62,63],"Jaundice","Newborn","Hyperbilirubinemia","Rebound hyperbilirubinemia","Phototherapy","Hemolysis","RECRUITING","2025-01-01",{"date":67,"type":32},"2025-01-03",{"date":69,"type":32},"2019-10-01",{"date":71,"type":22},"2027-01-01",{"name":73,"class":74},"Ministry of Health, Saudi Arabia","OTHER_GOV",1]